Esophageal Cancer Clinical Trial
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Summary
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
Full Description
Patients with locally advanced, unresectable or metastatic esophageal cancer (EC) or pancreatic ductal adenocarcinoma (PDAC) will receive futibatinib in combination with pembrolizumab plus standard of care (SOC) chemotherapy. Patients with EC will receive Investigator choice of chemotherapy (FP or mFOLFOX6), patients with PDAC will receive mFOLFIRINOX. Subjects will receive futibatinib in combination with pembrolizumab plus standard of care (SOC) chemotherapy during induction phase of the study and will continue on futibatinib in combination with pembrolizumab in consolidation phase.
Eligibility Criteria
Inclusion criteria
Is ≥18 years of age at the time of informed consent
Cohort A: Histologically or cytologically confirmed, locally advanced, unresectable or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the esophagogastric junction (EGJ).
Cohort B: Histologically or cytologically confirmed, locally advanced, unresectable or metastatic pancreatic ductal adenocarcinoma.
No prior systemic treatment for locally advanced, unresectable or metastatic disease
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Adequate organ function
Able to take medications orally
Exclusion Criteria
Has locally advanced disease that is resectable or potentially curable with radiation therapy (as determined by local investigator).
Has an adenocarcinoma histology and is eligible to receive approved targeted therapy (eg, HER-2 positive patients).
Has received prior treatment with an anti-PD-1/immunotherapy-drugs-are-boosting-survival/" >PD-L1 or FGF/FGFR targeting drug, or any other agent directed to stimulatory or co-stimulatory T-cell receptor.
Has known additional malignancy that is progressing or requires active treatment.
History or current evidence of calcium and phosphate homeostasis disorder
Current evidence of clinically significant retinal disorder
Pregnant or lactating female.
Has known hypersensitivity or severe reaction to any of the study drugs or their excipients.
Has a diagnosis of immunodeficiency.
Has known human immunodeficiency virus (HIV) and/or history of Hepatitis B or C infections, or known to be positive for Hepatitis B antigen (HBsAg)/ Hepatitis B virus (HBV) DNA or Hepatitis C antibody or RNA.
Has an active autoimmune disease that has required systemic treatment in the past 2 years
Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis.
Has had an allogenic tissue/organ transplant.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 22 Locations for this study
Santa Monica California, 90404, United States More Info
Principal Investigator
Denver Colorado, 80218, United States More Info
Principal Investigator
Miami Beach Florida, 33140, United States More Info
Principal Investigator
Tampa Florida, 33612, United States More Info
Principal Investigator
Detroit Michigan, 48202, United States More Info
Principal Investigator
Mickleton New Jersey, 08056, United States More Info
Principal Investigator
Buffalo New York, 14203, United States More Info
Principal Investigator
Canton Ohio, 44718, United States More Info
Principal Investigator
Horsham Pennsylvania, 19044, United States More Info
Principal Investigator
Nashville Tennessee, 37232, United States More Info
Principal Investigator
Dallas Texas, 75216, United States More Info
Principal Investigator
Fairfax Virginia, 22031, United States More Info
Principal Investigator
Roanoke Virginia, 24014, United States More Info
Principal Investigator
Seattle Washington, 98101, United States More Info
Principal Investigator
La Crosse Wisconsin, 54601, United States More Info
Principal Investigator
Lille Cedex , 59037, France More Info
Principal Investigator
Poitiers , 86000, France More Info
Principal Investigator
Frankfurt , 60488, Germany More Info
Principal Investigator
Barcelona , 08035, Spain More Info
Principal Investigator
Madrid , 28041, Spain More Info
Principal Investigator
How clear is this clinincal trial information?